CA
NZ
UK
AU
IND
US
…
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Barinthus Biotherapeutics plc is a NASDAQ-listed biopharmaceutical company; publicly available information about its pipeline and operations is limited. Long-term growth may depend on progress in clinical programs, successful regulatory milestones and commercialization partnerships, which could support value creation for investors.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -68.79M | -61.23M | -76.82M | 0.85M | -51.14M |
| Minority interest | 0.03M | 0.11M | 0.08M | 0.02M | -0.25M |
| Net income | -66.43M | -61.07M | -73.63M | 5.34M | -50.87M |
| Selling general administrative | 40.83M | 29.67M | 39.84M | 6.39M | 25.12M |
| Selling and marketing expenses | - | - | 0.15M | - | - |
| Gross profit | -5.86M | 14.97M | 0.80M | 44.70M | 0.27M |
| Reconciled depreciation | 5.84M | 5.80M | 5.17M | 4.32M | 0.60M |
| Ebit | -54.18M | -61.17M | -76.49M | 0.87M | -40.89M |
| Ebitda | -48.34M | -55.37M | -71.06M | 5.19M | -40.28M |
| Depreciation and amortization | 5.84M | 5.80M | 5.43M | 4.32M | 0.60M |
| Non operating income net other | - | - | - | - | -3.25M |
| Operating income | -54.19M | -67.97M | -84.24M | -4.04M | -45.22M |
| Other operating expenses | 54.19M | 82.94M | 85.04M | 47.50M | 41.49M |
| Interest expense | 0.05M | 0.05M | 0.03M | 0.02M | 2.67M |
| Tax provision | -0.17M | -0.04M | -4.27M | -4.47M | -0.03M |
| Interest income | 1.96M | 2.68M | 3.63M | 3.10M | 0.00M |
| Net interest income | 1.91M | 2.62M | 3.59M | 3.08M | -2.67M |
| Income tax expense | -0.20M | -0.04M | -3.09M | -4.47M | -0.03M |
| Total revenue | 0.00M | 14.97M | 0.81M | 44.70M | 0.27M |
| Total operating expenses | 48.34M | 82.94M | 85.04M | 47.50M | 41.49M |
| Cost of revenue | 5.86M | 5.80M | 0.00M | - | - |
| Total other income expense net | -14.60M | 6.74M | 7.42M | 0.57M | -7.25M |
| Net income from continuing ops | -66.46M | -61.18M | -77.32M | 5.32M | -51.11M |
| Net income applicable to common shares | - | - | - | - | -50.87M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 98.17M | 160.33M | 214.51M | 270.20M | 280.71M |
| Intangible assets | 14.29M | 21.95M | 25.11M | 28.27M | 31.43M |
| Other current assets | 6.03M | 2.08M | 9.91M | 8.27M | 6.46M |
| Total liab | 23.88M | 30.19M | 27.51M | 27.00M | 28.15M |
| Total stockholder equity | 74.21M | 130.03M | 186.78M | 242.90M | 252.12M |
| Other current liab | 6.25M | 7.11M | 9.21M | - | - |
| Common stock | 0.00M | 0.00M | 0.09M | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -304.09M | -237.66M | -176.59M | -103.24M | -108.58M |
| Good will | - | 0.00M | 12.21M | 12.21M | 12.63M |
| Cash | 70.46M | 110.66M | 142.09M | 194.38M | 214.05M |
| Total current liabilities | 10.02M | 15.66M | 12.60M | 12.24M | 11.16M |
| Current deferred revenue | 1.40M | 1.74M | - | - | - |
| Net debt | -59.17M | -98.66M | -129.11M | - | - |
| Short term debt | 2.02M | 1.92M | 1.78M | - | - |
| Short long term debt | - | - | - | - | 0.16M |
| Short long term debt total | 11.28M | 12.01M | 12.98M | - | - |
| Other stockholder equity | 393.94M | 393.56M | 386.60M | - | - |
| Total current assets | 77.79M | 125.74M | 156.91M | 213.04M | 226.76M |
| Net receivables | 1.30M | 13.00M | 4.91M | 5.85M | 0.02M |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 0.35M | 2.47M | 1.60M | 3.75M | 2.42M |
| Accumulated other comprehensive income | -15.73M | -25.87M | -23.32M | - | - |
| Non currrent assets other | 0.93M | 0.88M | 0.88M | 0.98M | 0.80M |
| Non current assets total | 20.38M | 34.59M | 57.60M | 57.16M | 53.95M |
| Capital lease obligations | 11.28M | 12.01M | 12.98M | 8.77M | 7.06M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.89M | -6.15M | -5.75M | -12.91M |
| Change to liabilities | - | - | - | - | 0.89M |
| Total cashflows from investing activities | 0.42M | -0.89M | - | - | -12.91M |
| Total cash from financing activities | 0.00M | 2.16M | 1.87M | 0.33M | 222.74M |
| Change to operating activities | - | - | - | - | -4.15M |
| Net income | -66.46M | -61.18M | -73.45M | 5.32M | -51.11M |
| Change in cash | -40.55M | -29.69M | -52.30M | -19.67M | 170.79M |
| Begin period cash flow | 112.40M | 142.09M | 194.38M | 214.05M | 43.27M |
| End period cash flow | 71.85M | 112.40M | 142.09M | 194.38M | 214.05M |
| Total cash from operating activities | -47.98M | -28.94M | -50.92M | -14.43M | -32.58M |
| Issuance of capital stock | 0.00M | 2.16M | 2.41M | 0.48M | 228.01M |
| Depreciation | 5.84M | 5.80M | 5.43M | 4.32M | 0.60M |
| Other cashflows from investing activities | -0.00M | - | - | - | -11.77M |
| Change to inventory | - | - | - | -0.65M | -4.15M |
| Change to account receivables | 6.42M | -2.35M | 5.80M | -5.83M | 0.56M |
| Sale purchase of stock | - | - | - | - | 100.60M |
| Other cashflows from financing activities | -0.00M | 2.16M | -0.16M | -5.75M | 119.97M |
| Change to netincome | - | - | - | - | 23.95M |
| Capital expenditures | 0.04M | 0.89M | 5.41M | 6.14M | 1.15M |
| Change receivables | - | - | - | - | 0.56M |
| Cash flows other operating | - | - | - | - | -7.47M |
| Cash and cash equivalents changes | - | - | - | - | 177.25M |
| Change in working capital | -0.36M | 2.60M | 6.17M | -5.52M | -7.18M |
| Stock based compensation | 0.47M | 4.71M | 5.05M | 9.88M | 16.49M |
| Other non cash items | 12.70M | 19.18M | 8.94M | -24.09M | 8.74M |
| Free cash flow | -48.02M | -29.83M | -56.34M | -20.57M | -33.73M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
20400 Century Boulevard, Germantown, MD, United States, 20874
443 917 0966
14
| Name | Title | Year Born |
|---|---|---|
| Mr. William J. Enright MBA | CEO & Director | 1962 |
| Dr. Nadege Pelletier Ph.D. | Chief Scientific Officer | 1979 |
| Mr. Graham Griffiths | Chief Business Officer | 1980 |
| Ms. Sarah Gilbert | Co-Founder | NA |
| Mr. Adrian Hill Ph.D. | Co-Founder & Scientific Advisor | NA |
| Ms. Gemma Brown | CFO & Company Secretary | 1991 |
| Ms. Elizabeth Eagling-Vose M.B.A. | Head of Clinical Operations | NA |
| Bernie McDonald | Head of IP | NA |
| Geoffrey Lynn | Senior Vice President of Synthetic Immunotherapies | NA |
| Mr. William James Enright MBA | CEO, Director, Secretary & Principal Financial Officer | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...